Dermatitis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Dermatitis stocks.

Dermatitis Stocks Recent News

Date Stock Title
May 14 KYMR Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
May 13 ARQT Arcutis Biotherapeutics Q1 2024 Earnings Preview
May 13 FBRX Forte Biosciences GAAP EPS of -$0.16
May 13 FBRX Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
May 13 BHC RBC Noes Bausch Health Filing For Rehearing in Appellate Court
May 13 REGN Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
May 13 REGN Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
May 13 APGE Apogee Therapeutics reports Q1 results
May 13 ARQT Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
May 13 APGE Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
May 13 REGN Pipeline Moves: Phase III completion for Corcept’s relaorilant
May 13 REGN Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
May 10 EDSA Edesa Biotech GAAP EPS of -$0.58 beats by $0.11
May 10 EDSA Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
May 10 REGN Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
May 10 REGN Q1 2024 Intellia Therapeutics Inc Earnings Call
May 9 VYNE VYNE Therapeutics GAAP EPS of -$0.15 beats by $0.09, revenue of $0.01M misses by $0.09M
May 9 VYNE VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
May 9 BHC Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
May 9 REGN Regeneron’s gene therapy triumphs twice, restoring hearing in children
Dermatitis

Dermatitis, also known as eczema, is a group of diseases that results in inflammation of the skin. These diseases are characterized by itchiness, red skin and a rash. In cases of short duration, there may be small blisters, while in long-term cases the skin may become thickened. The area of skin involved can vary from small to the entire body.Dermatitis is a group of skin conditions that includes atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and stasis dermatitis. The exact cause of dermatitis is often unclear. Cases may involve a combination of irritation, allergy and poor venous return. The type of dermatitis is generally determined by the person's history and the location of the rash. For example, irritant dermatitis often occurs on the hands of people who frequently get them wet. Allergic contact dermatitis occurs upon exposure to an allergen, causing a hypersensitivity reaction in the skin.Treatment of atopic dermatitis is typically with moisturizers and steroid creams. The steroid creams should generally be of mid- to high strength and used for less than two weeks at a time as side effects can occur. Antibiotics may be required if there are signs of skin infection. Contact dermatitis is typically treated by avoiding the allergen or irritant. Antihistamines may help with sleep and to decrease nighttime scratching.Dermatitis was estimated to affect 245 million people globally in 2015. Atopic dermatitis is the most common type and generally starts in childhood. In the United States, it affects about 10–30% of people. Contact dermatitis is twice as common in females than males. Allergic contact dermatitis affects about 7% of people at some point in time. Irritant contact dermatitis is common, especially among people who do certain jobs; exact rates are unclear.

Browse All Tags